Second, the therapeutic potential of targeting this axis is supported by our findings that both genetic interference (NGFR knockdown) and pharmacological interventions (ERK1/2 inhibition) effectively abrogate PHOX1-mediated oncogenic effects in GC. This evidence concerns the gene PRRX1 and gastric cancer.